Next-generation therapeutics for diabetic kidney disease

Area of Science:

• Nephrology
• Cardiology
• Endocrinology

Background:

• Diabetic kidney disease (DKD) is a major complication of diabetes mellitus, leading to kidney failure and increased mortality.
• DKD pathogenesis involves complex hemodynamic, metabolic, and inflammatory pathways driving renal damage.
• Current treatments offer cardiorenal protection but leave significant residual risk.

Purpose of the Study:

• To review current management strategies for DKD.
• To explore emerging next-generation therapies for DKD.
• To highlight the ongoing need for improved cardiorenal outcomes in DKD.

Main Methods:

• Literature review of current and developing DKD therapies.
• Analysis of the pathophysiology of DKD.
• Synthesis of evidence on guideline-directed medical therapy (GDMT) and novel agents.

Main Results:

• Current GDMT includes RAS inhibitors, SGLT2 inhibitors, MRAs, and GLP-1 RAs, often used in combination.
• Despite GDMT, substantial residual cardiorenal risk persists in DKD patients.
• Numerous next-generation therapies are in development, including incretin-based drugs, ET receptor antagonists, and anti-inflammatory agents.

Conclusions:

• Optimal GDMT is crucial for managing DKD and reducing cardiorenal risk.
• Emerging therapies hold promise to complement GDMT and further enhance outcomes.
• Continued research into novel treatments is essential for improving the prognosis of DKD.